InterCure Ltd. Stock TEL AVIV STOCK EXCHANGE

INCR

IL0011063760

Healthcare Facilities & Services

News in other languages : InterCure Ltd.

20-01-02

Tilray, Inc. : première exportation de cannabis vers Israël

More news

Managers and Directors : InterCure Ltd.

Manager	Title	Age	Since
Alexander Rabinovitch CEO	Chief Executive Officer	55	2019-12-23
Amos Cohen DFI	Director of Finance/CFO	47	2020-02-29
Itai Kabiljo LAW	General Counsel	-	2022-03-31

Director	Title	Age	Since
Lennie Michelson Grinbaum BRD	Director/Board Member	50	2015-09-02
David Salton BRD	Director/Board Member	66	2014-12-13
Alexander Rabinovitch CHM	Chairman	55	2025-02-12

More insiders

InterCure Ltd. is an Israel-based company engaged in the medical cannabis industry. Through its wholly owned subsidiary, Canndoc Ltd., the Company cultivates, produces, processes, markets, and distributes medical cannabis products. Its operations include the development and manufacture of pharmaceutical-grade medical cannabis products produced in accordance with Good Manufacturing Practice (GMP) standards. The Company offers a range of cannabis-based products for medical use and operates across various stages of the medical cannabis value chain, including cultivation, manufacturing, logistics, distribution, and retail activities. In addition, the Company is involved in the import, export, and commercialization of medical cannabis products and related healthcare solutions in Israel and selected international markets.

Employees

Sector

Healthcare Facilities & Services

More about the company

Market Cap	192M 578M 165M 155M 142M 265M 18.16B 267M 1.84B 715M 9.28B 722M 706M 29.89B	P/E 2024	-4.01x	P/E 2025	-4.87x
Enterprise Value	328M 988M 283M 265M 243M 453M 31.05B 456M 3.14B 1.22B 15.87B 1.23B 1.21B 51.11B	EV / Sales 2024	1.69x	EV / Sales 2025	1.16x
Free-Float	60.83%	Yield 2024 *	-	Yield 2025	-

Aug. 24	InterCure Ltd. announced that it has received ILS 21.711643 million in funding from Bennu Pharma Fund Ltd and other investors.	CI
Aug. 24	Intercure Ltd. Finalizes Settlement for War-Related Indirect Damages with the Israeli Tax Authorities and Compensation Fund the Subsequent War	CI
Jun. 22	InterCure Ltd. announced that it expects to receive ILS 21.711643 million in funding from Bennu Pharma Fund Ltd and other investors.	CI
Jun. 15	InterCure Starts Review of US Medical Cannabis Opportunities; Completes Initial Closing of Botanico Acquisition	MT
Jun. 14	InterCure Ltd. acquired 50% stake of Botanico Ltd.	CI
Jun. 14	InterCure Ltd. completed the acquisition of 50% stake in Botanico Ltd.	CI
Apr. 30	InterCure Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 03	InterCure Receives Noncompliance Notice From Nasdaq	MT
Mar. 03	InterCure receives Nasdaq notification regarding minimum bid requirement	RE
Feb. 19	InterCure announces preliminary estimated 2025 revenue of NIS 265 million, positive adjusted EBITDA and cash of NIS 43 million	RE
Dec. 18	InterCure Ltd on Dec 15, became aware that Bazelet Group of Companies has initiated Restructuring proceedings before the Israeli district court	RE
Nov. 03	Cannasoul Analytics Ltd. announced that it expects to receive funding from InterCure Ltd.	CI
Nov. 03	InterCure Ltd. Enters into A Collaboration Agreement with Cannasoul R&D Ltd	CI

Aug. 24	InterCure Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect Damages	AQ
Aug. 19	InterCure Ltd. Announces 1-for-5 Reverse Share Split	AQ
Jun. 22	InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds	AQ
Jun. 15	InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition	AQ
Apr. 30	InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTERCURE LTD.	+0.22%	-0.51%	-	-	63.9M
VILLAGE FARMS INTERNATIONAL, INC.	0.00%	-0.69%	+8.65%	+208.79%	354M
ORGANIGRAM GLOBAL INC.	+0.63%	-5.36%	-27.73%	-27.73%	161M
CANNARA BIOTECH INC.	+1.01%	+0.50%	+12.36%	+92.31%	142M
ASCEND WELLNESS HOLDINGS, INC.	-2.27%	+7.50%	-37.68%	-52.22%	89.41M
INTERCURE LTD.	+2.47%	-5.78%	-38.72%	-43.80%	63.9M
IANTHUS CAPITAL HOLDINGS, INC.	0.00%	0.00%	0.00%	-80.00%	25.29M
Average	+0.29%	-1.43%	-13.85%	+16.22%	139.3M
Weighted average by Cap.	+0.24%	-0.95%	-6.58%	+87.40%

	2024	2025
Net sales	239M 718M 206M 193M 176M 329M 22.58B 332M 2.28B 888M 11.54B 897M 877M 37.16B	270M 812M 232M 218M 200M 373M 25.54B 375M 2.58B 1.01B 13.05B 1.01B 993M 42.04B
Net income	-67.8M -204M -58.33M -54.74M -50.08M -93.47M -6.41B -94.21M -648M -252M -3.28B -255M -249M -10.55B	-35.71M -107M -30.72M -28.83M -26.38M -49.24M -3.38B -49.63M -341M -133M -1.73B -134M -131M -5.56B
Net Debt	133M 399M 114M 107M 98.07M 183M 12.55B 184M 1.27B 494M 6.41B 499M 488M 20.65B	136M 410M 117M 110M 101M 188M 12.89B 189M 1.3B 507M 6.59B 512M 501M 21.21B

InterCure Ltd. Stock TEL AVIV STOCK EXCHANGE

Stocks

INCR

IL0011063760

Healthcare Facilities & Services

Valuation : InterCure Ltd.

Latest news : InterCure Ltd.

Press Releases : InterCure Ltd.

News in other languages : InterCure Ltd.

Quotes and Performance

Managers and Directors : InterCure Ltd.

Medical Farming

Financials

Company Profile